Immunophenotyping of lymphoproliterative disorders: State of the art

Pathology

Volumn 37, Issue 6, 2005, Pages 457-478

  Gudgin, Emma J ^a   Erber, Wendy N ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Flow cytometry; Immunohistochemistry; Lymphoma; Lymphoproliferative; Phenotype

Indexed keywords

GENE PRODUCT; MONOCLONAL ANTIBODY; RITUXIMAB;

B CELL LYMPHOMA; B LYMPHOBLAST; B LYMPHOCYTE; BURKITT LYMPHOMA; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HAIRY CELL LEUKEMIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; LYMPHOCYTOMA; LYMPHOID TISSUE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MEDIASTINUM TUMOR; MINIMAL RESIDUAL DISEASE; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NEOPLASM; PHENOTYPE; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; REVIEW; SEZARY SYNDROME; T CELL LYMPHOMA; T LYMPHOBLAST; CLASSIFICATION; IMMUNOLOGY; METHODOLOGY; PATHOLOGY;

FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISORDERS; PHENOTYPE;

EID: 29744446424     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500368287     Document Type: Article

References (128)

1. Greaves M, Janossy G. Patterns of gene expression and the cellular origins of human leukaemias. Biochem Biophys Acta 1978; 516: 193-230.
2. Nakane P, Pierce G. Enzyme-labelled antibodies: preparation and application for the localisation of antigens. J Histochem Cytochem 1966; 14: 929-31.
3. Avrameas S. Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies. Immunochemistry 1969; 6: 43-52.
4. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-29.
5. Zeppa P, Marino G, Troncone G, et al. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer 2004; 102: 55-65.
6. Nasuti JF, Yu G, Boudousquie A, et al. Diagnostic value of lymph node fine needle aspiration cytology: an institutional experience of 387 cases observed over a 5-year period. Cytopathology 2000; 11: 18-31.
7. Ravoet C, Demartin S, Gerard R, et al. Contribution of flow cytometry to the diagnosis of malignant and non malignant conditions in lymph node biopsies. Leuk Lymphoma 2004; 45: 1587-93.
8. Mazur G, Halon A, Wrobel T, et al. Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin lymphomas. Neoplasma 2004; 51: 159-63.
9. Perea G, Altes A, Bellido M, et al. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). Histopathology 2004; 45: 268-74.
10. Stacchini A, Demurtas A, Godio L, et al. Flow cytometry in the bone marrow staging of mature B-cell neoplasms. Cytometry B Clin Cytom 2003; 54: 10-8.
11. Merz H, Malisius R, Mannweiler S, et al. ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab Invest 1995; 73: 149-56.
12. Bobrow MN, Harris TD, Shaughnessy KJ, et al. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods 1989; 125: 279-85.
13. Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods 1991; 137: 103-12.
14. Key ME, Phillips T. Catalysed signal amplification (CSA): An enhanced immunohistochemical staining method based on biotinyl tyramide. J NIH Res 1996; 8: 72-3.
15. Erber WN, Gibbs TA, Ivey JG. Antigen retrieval by microwave oven heating for immunohistochemical analysis of bone marrow trephine biopsies. Pathology 1996; 28: 45-50.
16. Bankfalvi A, Navabi H, Bier B, et al. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol 1994; 174: 223-8.
17. Miller K, Auld J, Jesseb E, et al. Antigen unmasking in formalin-fixed routinely processed paraffin wax-embedded sections by pressure cooking: a comparision with microwave oven heating and traditional methods. Adv Anat Pathol 1995; 2: 60-4.
18. Ko IK, Kato K, Iwata H. Antibody microarray for correlating cell phenotype with surface marker. Biomaterials 2005; 26: 687-96.
19. Belov L, de la Vega O, dos Remedios CG, et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 2001; 61: 4483-9.
20. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-26.
21. Jaffe ES, Harris NL, Stein H, et al., editors, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
22. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-6.
23. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112: 8-15.
24. Neale GA, Coustan-Smith E, Stow P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 934-8.
25. Kerst G, Kreyenberg H, Roth C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005; 128: 774-82.
26. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002; 9: 316-21.
27. Szatrowski TP, Dodge RK, Reynolds C, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 2003; 97: 1471-80.
28. Jandula BM, Nomdedeu J, Marin P, et al. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2001; 27: 225-7.
29. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004; 83: 201-5.
30. Szczepanski T, van der Velden VH, van Dongen JJ. Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol 2003; 16: 561-82.
31. Smith FO, Rauch C, Williams DE, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996; 87: 1123-33.
32. Schwartz S, Rieder H, Schlager B, et al. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia 2003; 17: 1589-95.
33. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931-9.
34. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233-58.
35. Fais F, Tenca C, Cimino G, et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 2005; 19: 551-6.
36. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115-20.
37. Veltroni M, De Zen L, Sanzari MC, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003; 88: 1245-52.
38. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-43.
39. Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002: 162-92.
40. Hyjek E, Chadburn A, Liu YF, et al. BCL6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. Blood 2001; 97: 270-6.
41. van der Velden VH, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002; 16: 1432-6.
42. Pui CH, Schrappe M, Ribeiro RC, et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004: 118-45.
43. Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 2004; 363: 535-6.
44. Oscier D, Fegan C, Hillmen P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294-317.
45. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-5.
46. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108: 378-82.
47. Kampalath B, Barcos MP, Stewart C. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2003; 119: 824-32.
48. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-14.
49. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
50. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
51. Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002; 87: 1021-7.
52. Mainou-Fowler T, Dignum HM, Proctor SJ, et al. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 2004; 45: 455-62.
53. Carter A, Lin K, Sherrington PD, et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425-8.
54. Chang CC, Lorek J, Sabath DE, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 4671-5.
55. Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res 2002; 93: 685-94.
56. Garcia Vela J, Delgado I, Benito L, et al. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia 1999; 13: 1501-5.
57. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
58. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-9.
59. Falini B, Pulford K, Erber WN, et al. Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocytochemical study of 36 cases. Histopathology 1986; 10: 671-87.
60. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82: 1277-87.
61. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 1994; 14 (Suppl 1): 57-61.
62. Quigley MM, Bethel KJ, Sharpe RW, et al. CD52 expression in hairy cell leukemia. Am J Hematol 2003; 74: 227-30.
63. Del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004; 89: 303-8.
64. Mori N, Murakami YI, Shimada S, et al. TIA-1 expression in hairy cell leukemia. Mod Pathol 2004; 17: 840-6.
65. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363: 1869-70.
66. Salomon-Nguyen F, Valensi F, Troussard X, et al. The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Leuk Res 1996; 20: 909-13.
67. Janckila AJ, Cardwell EM, Yam LT, et al. Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Blood 1995; 85: 2839-44.
68. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665-70.
69. Tytherleigh L, Taparia M, Leahy MF. Detection of hairy cell leukaemia in blood and bone marrow using multidimensional flow cytometry with CD45-PECy5 and SS gating. Clin Lab Haematol 2001; 23: 385-90.
70. Cornfield DB, Mitchell Nelson DM, Rimsza LM, et al. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells. Am J Hematol 2001; 67: 223-6.
71. Matutes E, Wotherspoon A, Brito-Babapulle V, et al. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001; 15: 184-6.
72. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 41-56.
73. Cessna MH, Hartung L, Tripp S, et al. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 2005; 123: 132-8.
74. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996; 93: 731-6.
75. Dogan A, Isaacson PG. Splenic marginal zone lymphoma. Semin Diagn Pathol 2003; 20: 121-7.
76. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83: 1558-62.
77. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004; 45: 2007-15.
78. Kaptain S, Zuckerberg LR, Ferry JA. BCL1 cyclin D1+CD5- mantle cell lymphoma. Mod Pathol 1998; 11: 133a.
79. Schraders M, de Jong D, Kluin P, et al. Lack of BCL2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205: 329-35.
80. Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99: 1959-64.
81. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-52.
82. Flenghi L, Ye BH, Fizzotti M, et al. A specific monoclonal antibody (PG-B6) detects expression of the BCL6 protein in germinal center B cells. Am J Pathol 1995; 147: 405-11.
83. Jardin F, Buchonnet G, Parmentier F, et al. Follicle center lymphoma is associated with significantly elevated levels of BCL6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements. Leukemia 2002; 16: 2318-25.
84. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005; 105: 3979-86.
85. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-21.
86. Ogawa S, Yamaguchi M, Oka K, et al. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. Br J Haematol 2004; 125: 180-6.
87. Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin lymphoma: the role of BCL6. Leuk Lymphoma 2003; 44 (Suppl 3): S5-12.
88. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
89. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
90. de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509-28.
91. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-72.
92. Ansell SM, Stenson M, Habermann TM, et al. CD4+ T-cell immune response to large B-cell non-Hodgkin lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-6.
93. Xu Y, Kroft SH, McKenna RW, et al. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol 2001; 112: 945-9.
94. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162: 243-53.
95. Calaminici M, Piper K, Lee AM, et al. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004; 45: 619-24.
96. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-9.
97. Marafioti T, Pozzobon M, Hansmann ML, et al. Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia 2005; 19: 856-61.
98. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543-9.
99. Rodig SJ, Savage KJ, Nguyen V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005; 29: 196-203.
100. Lin CW, O'Brien S, Faber J, et al. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol 1999; 112: 828-35.
101. Frost M, Newell J, Lones MA, et al. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384-92.
102. Brown DC, Gatter KC, Mason DY. Proliferation in non-Hodgkin lymphoma: a comparison of Ki-67 staining on fine needle aspiration and cryostat sections. J Clin Pathol 1990; 43: 325-8.
103. Pich A, Ponti R, Valente G, et al. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 1994; 47: 18-22.
104. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 57-68.
105. Ye H, Gong L, Liu H, et al. MALT lymphoma with t(14;18)(q32;q21)/IGH- MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 2005; 205: 293-301.
106. El-Zimaity HM, El-Zaatari FA, Dore MP, et al. The differential diagnosis of early gastric mucosa-associated lymphoma: polymerase chain reaction and paraffin section immunophenotyping. Mod Pathol 1999; 12: 885-93.
107. Jamal S, Picker LJ, Aquino DB, et al. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001; 116: 512-26.
108. Gorczyca W, Weisberger J, Liu Z, et al. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Cytometry 2002; 50: 177-90.
109. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165-73.
110. Morice WG, Kimlinger T, Katzmann JA, et al. Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. Am J Clin Pathol 2004; 121: 373-83.
111. Matutes E. Chronic T-cell lymphoproliferative disorders. Rev Clin Exp Hematol 2002; 6: 401-20.
112. Toyota S, Nakamura N, Dan K. Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype. Int J Hematol 2005; 81: 66-8.
113. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667-72.
114. Valbuena JR, Herling M, Admirand JH, et al. T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol 2005; 123: 456-64.
115. Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004; 104: 328-35.
116. Langerak AW, Sandberg Y, van Dongen JJ. Spectrum of T-large granular lymphocyte lymphoproliferations: ranging from expanded activated effector T cells to T-cell leukaemia. Br J Haematol 2003; 123: 561-2.
117. Aldinucci D, Poletto D, Lorenzon D, et al. CD26 expression correlates with a reduced sensitivity to 2′-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 2004; 10: 508-20.
118. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2001: 259-81.
119. Kothapalli R, Bailey RD, Kusmartseva I, et al. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol 2003; 22: 33-9.
120. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol 2001; 144: 125-35.
121. Rappl G, Muche JM, Abken H, et al. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sezary syndrome. J Am Acad Dermatol 2001; 44: 456-61.
122. Ohshima K, Haraoka S, Suzumiya J, et al. Absence of cytotoxic molecules in CD8- and/or CD56-positive adult T-cell leukaemia/lymphoma. Virchows Arch 1999; 435: 101-4.
123. Takeshita M. CD30-positive anaplastic large cell lymphoma with HTLV-I proviral integration: a unique histologic subgroup of adult T-cell leukemia/lymphoma. Intern Med 1999; 38: 757-8.
124. Pittaluga S, Wlodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997; 151: 343-51.
125. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.
126. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001; 25: 285-96.
127. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-13.
128. Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-70.